Nasdaq:US$16.50 (+0.14) | HKEX:HK$26.00 (-0.10) | AIM:£2.70 (-0.01)
搜索
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer